Sanofi to Expand OTC Unit with Boehringer Swap Deal
Total Page:16
File Type:pdf, Size:1020Kb
OTC15-01-16p1_OTC15/11/2005 p1&24 12/01/2016 14:55 Page 1 15 January2016 COMPANY NEWS 3 Sanofi to expand OTC unit Mylan remains determined 3 to expand its OTCbusiness Stada snaps up Argentine base 3 with Boehringerswap deal India’s Piramal bolstersits 4 OTCunit with Merck brands Perrigo favoursgenerics with 5 anofiisset to become one of the world’s OTCswitch potential Stop-three consumer healthcarecompa- Bayersells offPro Plus brand 5 nies after announcing it is in exclusive talks to exchangeits Merial animal healthcare WBA eyes expansion 6 in Latin America business forBoehringer Ingelheim’s Con- Johnson &Johnson seeks 7 sumer Health Careunit. innovations in oral care The proposed deal –which is expected to Eris snaps up Halykoo rights 7 close in the fourth quarter of 2016 –would see Sanofigain Boehringer’sConsumer Health UK starts investigation of 8 Celesio/Sainsbury’s tie-up Care business in all markets except China and create aglobal OTCdivision with proforma GENERAL NEWS 9 sales of approximately C5.1 billion. This, Sanofi claimed, would give the division aglobal mar- Racecadotril OTCswitch 9 ketshare of “close to” 4.6%. Vincent Warnery, head of Sanofi’s global Consumer gets green light in Germany The combined business, Sanofiadded, would Healthcarebusiness, said the deal with Boehringer would enable the firmtobetter serve consumers TGAexpands its 10 be the world leader in OTCdigestive health and codeine consultation feminine-care products, as well as number two mentarity of our respective consumer healthcare Fake supplements increase in India 10 in pain care (see Figure 1). businesses,”headded, “from both aproduct German marketenjoys a 11 When the transaction is completed, Sanofi’s portfolio and geographic coverage standpoint.” 7% increase in OTCdrugs Consumer Healthcarebusiness will become one Echoing Warnery’scomments, Olivier Brand- Desloratadine switch proposed 11 of the world’sbiggest and on apar with the two icourt, the French firm’schief executive officer, Health Canada warns on 14 global leaders, GlaxoSmithKline (GSK) Con- said that adding Boehringer’sConsumer Health OTCtopical acne products sumer Healthcare and Bayer Consumer Care. Care unit to its existing Consumer Healthcare GSK hits back at pricing criticism 14 Speaking exclusively to OTC bulletin,Vin- business would makeita“world leader in the cent Warnery,head of the French group’sglobal attractive non-prescription medicines market” MARKETING NEWS 15 Consumer Healthcaredivision, said that “as with a“complementary portfolio of highly- Australia ordersNurofen 15 recently underscored in Sanofi’s2020 strategic recognised brands” that would allow“mid- to from shelves roadmap, consumerhealthcare is definitely an long-term value creation”. Typharm aims to reposition 16 area where the firm wants to growfurther”. The proposed transaction would consist of Docusol Paediatric as OTC “The intended business swap with Boeh- an exchange of Sanofi’sMerial animal health- SanofioffersUSmore pain relief 16 ringer would –subject to approvals –offer care business –which has an enterprise value opportunitiestoevenbetter serveconsumers of C11.4 billion –for Boehringer’sConsumer Pfizer adds twonew variants to 17 its Centrum line in France around the world, thanks to the great comple- ■ Continued on page 23 MHRA approves firste-cig 18 Combined global categories Market position of Value of global market as NRTmedicine in the UK combined business (C billions) Perrigo launches MucinexDrival 18 Vitamins, minerals and supplements #3 27.6 FEATURES 20 Cough and cold care #6 17.2 Digestive health #1 14.4 Protecting prices 20 in ahybrid world Pain care #2 13.2 Allergy solutions #3 3.1 REGULARS Feminine care #1 0.8 Events – Our regular listing 19 Total combined global categories –76.3 People – Valeant names interim CEO 23 Total global market –~110 as Pearson takes sick leave Figure1:Market position of Boehringer Ingelheim and Sanofi’s combined global categories (Source –Sanofi) Health conversations are changing. With GP appointments increasingly difficult to secure, we’re turning to the internet for medical advice. But when there’s a wealth of different information out there, how do you know who to trust? NetDoctor, one of the UK’s leading sources of health information showcases content that is as dependable as it is engaging. Published in collaboration with over 250 respected medical professionals, users are empowered to make better choices about their wellbeing. 6 MILLION VISITORS EVERY MONTH* *Google Analytics November 2015 www.netdoctor.co.uk OTC_Advert.indd 1 05/01/2016 13:28 OTC15-01-16p2-8_Layout 1 12/01/2016 16:15 Page 3 COMPANY NEWS OTC Mergers&Acquisitions BusinessStrategy Stada snaps up Mylan remains determined Argentinebase to expandits OTC business tada Arzneimittel is set to acquire privately- Sowned Argentinian generics manufacturer espite failing to acquire Perrigo late last have to rely on “one broad-brush approach”. Laboratorio Vannier for US$13.0 million (C11.8 Dyear,Mylan remains interested in expand- “It doesn’tjust have to be this ‘big bang’ million) in amove the companyclaims will ingits presence in the European and US OTC to deliverreturns,”she insisted. “It’sabout opti- give it aplatform for launching its OTCprod- markets, according to the firm’schief executive mising the assets we already have.” ucts into the country.The deal is expected to officer Heather Bresch. Noting that the firm had recently appointed close by the end of this month. Speaking to delegates at arecent Goldman Ranjan Ray Chaudhuri to head up its OTCop- Under the terms of the agreement, Stada will Sachs healthcare conference in Boston, US, erations (OTC bulletin,6November 2015, page gain Buenos Aires-based Vannier’sportfolio of Bresch said the generics giant had not been 27), Bresch said this wasaclear indication generics –covering the cardiovascular,central putoff by the Perrigo rejection (OTC bulletin, that Mylan wanted “really to put afocus” on nervous system and diabetes categories –which 27 November 2015, page 1) and planned to developing its OTCbusiness. generatedsales of C7.0 million in the 12 months “continue on apath with OTC”. Chaudhuri brought to the role almost 30 years ended 31 August 2015. While Bresch admitted that gaining Perrigo of experience at GlaxoSmithKline (GSK), hav- would have significantly “accelerated” Mylan’s ing recently led the sale of the firm’sNiQuitin Introduce OTC brands entrance into the OTCmarket, she insisted that nicotine-replacement therapy(NRT) brand in Dr Matthias Wiedenfels, amember of Stada’s the firm “did not need” the US store-brandspe- the European Economic Area (EEA) to Perrigo. executive board, said that as well as marketing cialist to build anon-prescription medicines line. Mylan has expressed an interest in build- Vannier’sgeneric medicines, the firm planned “Perrigo wasone waytoget there, butlike ing its presence in the OTCmarket for some to use the “network, production and selling we said at the time, there are other ways,” time. In mid-2014, the companysaid it intend- power of Vannier” to introduce its ownOTC Bresch noted. “There are product acquisition ed to explore opportunitiestobuild an OTC brands to the Argentinian market. opportunities, there are other companies.” operation in Europe to complement its US$5.3 Aspokesperson for the companytold OTC On the acquisition front, Bresch promised billion (C4.9 billion) purchase from Abbott of bulletin that the planned move would be the that Mylan would “continue to be very active” aroster of more than 100 mature brands and first time Stada’sBranded Products were avail- and seek out “companies that either give us crit- branded generics (OTC bulletin,15August able in South America. ical mass in adifferent channel or geography”. 2014, page 3). Stada first gained apresence in the South However, acquiring firms wasjust one route At the time, Bresch told investors that Mylan American market in 2002 when it established to gain critical mass in the OTCspace, Bresch thought OTCwas an “interesting channel” that ajoint venture with AVA Industrialtodistribute noted. There existed “lots” of other “creative in “some respects is even more interesting out- its generics across Brazil. ways” to build apresence –such as partner- side the US”. OTC ships –Bresch said, noting that Mylan did not OTC 15 January 2016 Number 455 Individual subscriptions Terms & Conditions: An annual subscription comprises: These can be viewed infull at Editor: Matt Stewart www.OTC-bulletin.com/subscribe. Editor-in-Chief: Aidan Fry ■ 20 OTC bulletin newsletters; ■ AND at least 45 weekly news@OTCbulletin No partofthis publication maybecopied, reproduced, Production Editor: Jenna Meredith stored in aretrieval system, distributed or transmitted by electronic newsflashes containing the week’s Assistant Editors: To mGallen, Marie McEvoy anymeans, including electronic,mechanical, photocopying top news stories (currentlydelivered by email). Contributing Editor: David Wallace or recording, without the prior written permission of the publisher,orunder the terms and conditions of Advertising Controller: Debi Minal Choice of formats aGlobal Site Licence or of alicence issued by the Director of Subscriptions:ValDavis The 20 OTC bulletin newsletters areavailable: Copyright Licensing Agency (CLA) in London, UK, or Group Sales Manager: Rob Coulson ■ EITHER as the digital OTC bulletin-i for rights bodies in other countries that have reciprocal Awards Manager: Natalie Cornwell online access by desktop,and tablet and agreements with the CLA. Managing Director: